Similar articles

• Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.

  Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, Kozloff MF, Clark JI, Yan DH, Liu W, Pierce C, Dancey JE, Stenson K, Blair E, Dekker A, Vokes EE. Cohen EE, et al. Lancet Oncol. 2009 Mar;10(3):247-57. doi: 10.1016/S1470-2045(09)70002-6. Epub 2009 Feb 7. Lancet Oncol. 2009. PMID: 19201650 Free PMC article. Clinical Trial.
• Salvage with erlotinib plus bevacizumab: not in NSCLC.

  Sculier JP, Meert AP, Berghmans T. Sculier JP, et al. Lancet. 2011 May 28;377(9780):1810-2. doi: 10.1016/S0140-6736(11)60740-X. Lancet. 2011. PMID: 21621709 No abstract available.
• Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions.

  Forastiere AA, Burtness BA. Forastiere AA, et al. J Clin Oncol. 2007 Jun 1;25(16):2152-5. doi: 10.1200/JCO.2007.10.9017. J Clin Oncol. 2007. PMID: 17538157 No abstract available.
• Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC.

  Herbst RS, Sandler A. Herbst RS, et al. Oncologist. 2008 Nov;13(11):1166-76. doi: 10.1634/theoncologist.2008-0108. Epub 2008 Nov 8. Oncologist. 2008. PMID: 18997180 Review.
• [Head and neck: molecular-targeted therapy].

  Tsukuda M. Tsukuda M. Gan To Kagaku Ryoho. 2007 Jul;34(7):1034-9. Gan To Kagaku Ryoho. 2007. PMID: 17682304 Review. Japanese. No abstract available.